

Reference:	FOI.19209.26
Subject:	Biologic medicines in Dermatology
Date of Request:	2 January 2026

Requested:

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Apremilast
 - Bimekizumab
 - Brodalumab
 - Certolizumab
 - Deucravacitinib
 - Dimethyl fumarate
 - Etanercept - Enbrel
 - Etanercept Biosimilar
 - Guselkumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Ixekizumab
 - Risankizumab
 - Secukinumab
 - Tildrakizumab
 - Ustekinumab - Stelara
 - Ustekinumab Biosimilar
 - Omalizumab
 - Spesolimab

2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Bimekizumab
 - Certolizumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Secukinumab
 - Ustekinumab - Stelara
 - Ustekinumab Biosimilar

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low number (less than 5) and have therefore, replaced the figures in the tables with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection

Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides, within the table below, the number of Dermatology patients treated for any medical condition, with the listed medications, during the period 1 October to 31 December 2025.

Medication	Number
Adalimumab – Humira	*
Adalimumab Biosimilar	104
Apremilast	7
Bimekizumab	*
Brodalumab	*
Certolizumab	0
Deucravacitinib	0
Dimethyl fumarate	*
Etanercept – Enbrel	0
Etanercept Biosimilar	*
Guselkumab	*
Infliximab – Remicade	0
Infliximab Biosimilar	0
Ixekizumab	0
Risankizumab	32
Secukinumab	42
Tildrakizumab	*
Ustekinumab - Stelara	0
Ustekinumab Biosimilar	30
Omalizumab	15
Spesolimab	0

2. The UHB provides within the table below the number of Dermatology patients treated for Hidradenitis Suppurativa (HS), with the listed medications, during the period 1 October to 31 December 2025.

Medication	Number
Adalimumab - Humira	0
Adalimumab Biosimilar	16
Bimekizumab	0
Certolizumab	0
Infliximab - Remicade	0
Infliximab Biosimilar	0
Secukinumab	*
Ustekinumab - Stelara	0
Ustekinumab Biosimilar	0